Shaping a better future for people with severe blood disorders
Pioneering in vivo genetic medicines
We are developing targeted treatments to transform the lives of people with sickle cell disease, beta thalassemia and other severe blood diseases. Our therapeutics are designed to be safer and more effective than existing options.
Learn about our progress
Striking at the core of hematologic diseases
Our antibody bioconjugates specifically target the bone marrow cells affected by multiple severe blood diseases, with the potential to achieve sustained benefit.
Learn about our approach
Engineering a new future
Our team has deep experience and expertise developing tissue-targeted therapeutics. We are committed to working together to deliver groundbreaking medicines for patients.
Meet our team